$19.99 Flat-Rate US Shipping

Savannah Peptide

Peptide Library

A reference list of research compounds, written from published studies. Entries describe what laboratories and clinical trials have examined — not how to use a vial, and not as medical advice.

74 compounds

Metabolic

13

Adipotide, also described as a fat-targeted proapoptotic peptide (FTPP), is a peptidomimetic designed to bind prohibitin in the blood vessels of white adipose tissue and trigger cell death in those vessels. Published work is preclinical.

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also called acadesine) is a cell-permeable precursor of ZMP that has been used to activate AMP-activated protein kinase (AMPK) in laboratory and clinical research. It is a nucleoside analog rather than a ribosomal peptide.

AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone (residues 177–191) with a tyrosine substitution at the N-terminus. Preclinical papers have examined fat oxidation and body-weight change in rodent models, and later work has looked at joint models.

Cagrilintide is a long-acting analog of amylin developed for metabolic research and clinical trials of weight management. It has been studied on its own and together with semaglutide (a combination often called CagriSema).

Blend

CagriSema is the name used in clinical research for cagrilintide combined with semaglutide. Savannah's research vials are described as a two-peptide blend of those components in equal amounts. Published trials used defined pharmaceutical products under clinical protocols, which are not the same as a research-grade vial.

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used in clinical research and approved medical products for type 2 diabetes. Large randomized trials have examined glycemic control and cardiovascular outcomes. A research vial is not the same as a licensed pharmaceutical product.

Mazdutide is an investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors. Randomized trials in Chinese adults have examined type 2 diabetes and overweight or obesity. A research vial is not a licensed medicine.

In stock at Savannah

MOTS-c is a short peptide encoded by a mitochondrial open reading frame of the 12S rRNA gene. Published work is largely in mice and in cell models of metabolism, exercise, and muscle aging.

View MOTS-c in the catalog

In stock at Savannah

Retatrutide (also studied as LY3437943) is an investigational peptide that activates the receptors for GIP, GLP-1, and glucagon. Phase 2 trials in people with obesity and in people with type 2 diabetes have been published in major journals. A research vial is not a licensed medicine.

View Retatrutide in the catalog

Semaglutide is a long-acting GLP-1 receptor agonist. Licensed products have been studied in large randomized trials for type 2 diabetes and for weight management, typically as a once-weekly subcutaneous dose in those protocols. A research vial is not a licensed pharmaceutical product.

Survodutide is an investigational peptide that activates both the glucagon and GLP-1 receptors. Randomized trials have examined once-weekly administration in adults with obesity and in metabolic dysfunction-associated steatohepatitis (MASH). A research vial is not a licensed medicine.

In stock at Savannah

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Licensed products have been studied in large randomized trials for type 2 diabetes and for obesity, typically as once-weekly subcutaneous doses in those protocols. A research vial is not a licensed pharmaceutical product.

View Tirzepatide in the catalog

Liraglutide is a once-daily GLP-1 receptor agonist. Licensed products have been studied in large randomized trials for type 2 diabetes and for weight management. Savannah does not currently list a liraglutide product; this entry is included because the trial literature is extensive and is often compared with later weekly GLP-1 medicines.

Recovery / Tissue

9

ARA-290 (cibinetide) is a short peptide engineered from erythropoietin. It was designed to engage tissue-protective signaling without stimulating red-cell production. Published clinical papers have examined small-fiber neuropathy, including in people with sarcoidosis, and laboratory papers have used nerve and kidney injury models.

B7-33 is a single-chain peptide analog related to relaxin-2 (serelaxin). Laboratory papers describe it as a functionally selective agonist of relaxin family peptide receptor 1 (RXFP1). Published work is preclinical.

BPC-157 is a synthetic 15-amino-acid peptide originally derived from a sequence in gastric juice. Most published work is in rodents, often from a small number of laboratories, looking at tendon, muscle, gut, and vascular injury models. Human reports are limited to small, uncontrolled pilots; no randomized controlled trials were among the sources opened for this page.

BlendIn stock at Savannah

This research blend combines BPC-157 with TB-500, a synthetic fragment related to thymosin beta-4. Each component has its own preclinical literature; studies of the combination are fewer.

View BPC-157 + TB-500 Blend in the catalog

GDF-8 is myostatin, a protein that normally limits skeletal-muscle growth. Research on this pathway more often studies myostatin inhibition than administration of the protein itself. One early paper showed that giving myostatin systemically can induce cachexia in mice, which is the opposite of muscle growth.

KPV is a C-terminal tripeptide of α-melanocyte-stimulating hormone. Laboratory papers have examined it in intestinal and inflammatory-bowel models, including uptake through the peptide transporter PepT1.

LL-37 is the C-terminal peptide of human cathelicidin (hCAP18), an antimicrobial and immunomodulatory peptide. Clinical-research papers have examined it in hard-to-heal venous leg ulcers and have also described dermatologic toxicity in a melanoma study.

PEG-MGF is a pegylated form of mechano growth factor, a splice variant related to the IGF-I family, sometimes discussed in sports-science literature. Among the sources opened for this page, no primary dosing study of pegylated MGF itself was verified, so no study-dosing details are listed here. A 2026 review of performance-enhancing peptides that modulate the GH–IGF-I axis discussed this class in general terms (Dominikowski et al., Front Endocrinol, PMID 42395176).

TB-500 is the name used in research-chemical catalogs for a synthetic peptide related to thymosin beta-4, a 43-amino-acid actin-binding protein. Formal clinical papers generally study recombinant thymosin beta-4 rather than a catalog fragment. Those papers should not be read as studies of a research-grade TB-500 vial.

Cognitive

10
In stock at Savannah

Adamax is a synthetic research analog related to Semax, a modified fragment of adrenocorticotropic hormone (ACTH). It is sold in research-chemical catalogs, sometimes with more than one reported chemical structure under the same name.

View Adamax in the catalog

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids prepared from porcine brain, not a single defined sequence. Controlled trials and Cochrane reviews have examined it in acute ischaemic stroke and in other neurological conditions. Review authors have often judged the evidence to be uncertain.

Cortagen is a short tetrapeptide examined in nerve-regeneration and brain-injury models, mainly in animal and biochemical papers from one research group.

Delta sleep-inducing peptide (DSIP) is a nonapeptide first described in sleep research. Human studies from the 1980s and 1990s examined sleep recordings in people with insomnia, and later work looked at anesthesia-related EEG measures. A 2006 review still described aspects of its biology as unresolved.

P21, also published as P021, is a neurotrophic peptidergic compound studied mainly in mouse models of Alzheimer-like pathology, including oral chronic-treatment papers from one research program. Human trials were not among the sources opened for this page.

PE-22-28 is a shortened analog of spadin, a peptide that blocks the TREK-1 potassium channel. Published work is preclinical and has examined depression- and stroke-related models in animals.

Pinealon is a short peptide from the same bioregulatory research line as several other pineal and brain peptides. Published papers are limited and include clinical-observational reports from one group, often mixing several peptides, so attribution to pinealon alone is difficult.

In stock at Savannah

Selank is a synthetic heptapeptide analog of tuftsin developed in Russian laboratories. Published clinical papers, many in Russian-language journals, have examined it in people with anxiety disorders. Animal papers have looked at stress, memory, and withdrawal models. A research vial is not a licensed medicine in the United States.

View Selank in the catalog

Semax is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH 4–10) with a Pro-Gly-Pro C-terminal extension. It has been studied in Russian clinical papers on ischaemic stroke and in laboratory work on brain-derived neurotrophic factor and neural circuitry. A research vial is not a licensed medicine in the United States.

Dihexa is a metabolically stabilized angiotensin IV analog studied in cell and animal models of synaptic growth and memory-related tasks. Published work is preclinical. Savannah does not currently list a dihexa product; it is included because several primary laboratory papers are available.

Cosmetic / Skin

9

AHK-Cu is a copper complex of the tripeptide alanine-histidine-lysine. Laboratory papers have examined it in hair-follicle and cell-culture models. It is distinct from the better-known GHK-Cu tripeptide.

In stock at Savannah

GHK-Cu is a naturally occurring copper-binding tripeptide that has been studied in skin, fibroblast, and wound-related laboratory models, and in some topical clinical and cosmetic investigations. It is one of the better-documented cosmetic-research peptides.

View GHK-Cu in the catalog

Blend

Savannah describes GLOW as a three-peptide research blend containing BPC-157 10 mg, GHK-Cu 50 mg, and TB-500 10 mg per vial (70 mg total). Indexed primary trials of this exact three-peptide combination were not among the sources opened for this page. Component studies are summarized on the BPC-157, GHK-Cu, and TB-500 entries.

Blend

Savannah describes KLOW as a four-peptide research blend containing BPC-157 10 mg, GHK-Cu 50 mg, TB-500 10 mg, and KPV 10 mg per vial (80 mg total). Indexed primary trials of this exact four-peptide combination were not among the sources opened for this page. Component studies are summarized on the individual entries.

Matrixyl is a trade name for palmitoyl pentapeptide-4 (often palmitoyl-KTTKS), a signal peptide used in topical cosmetic research. Published work includes facial-skin appearance studies of topical creams and comparisons with other cosmetic peptides.

MT-1 (melanotan I, afamelanotide) is a linear analog of α-melanocyte-stimulating hormone. An approved implant of afamelanotide has been studied for erythropoietic protoporphyria, and randomized work has also examined it with phototherapy in vitiligo. A research vial is not the licensed implant product.

Melanotan II is a cyclic analog of α-melanocyte-stimulating hormone. Early clinical-research papers examined pigmentation and sexual function. It is not an approved drug, and case reports have described harms after unregulated use.

PTD-DBM is a competing peptide designed to interfere with CXXC5 in Wnt/β-catenin signaling. Published work is in hair-growth and wound-induced hair-neogenesis models in mice, not in large human drug trials.

SNAP-8 is a trade name for an acetyl octapeptide related to the SNAP-25 protein, used in topical cosmetic research as a companion to earlier hexapeptide (Argireline-type) ingredients. Published clinical work is in cosmetic cream or microneedle-patch settings, not in systemic drug trials.

Longevity

11

Bronchogen is a short peptide studied mainly by one research group in lung and bronchial epithelium models, including work on aging cell cultures and an obstructive lung-injury model. The published literature is limited and largely preclinical.

Cardiogen is a short peptide examined mainly in cardiac cell-culture and animal papers from one research group, including work on myocardial tissue cultures and a sarcoma model in senescent rats. Published evidence is limited.

Cartalax is a short peptide studied in aging cell-culture models, including skin fibroblasts and kidney cultures. The literature is limited and largely in vitro.

Crystagen is a short peptide with a very small published record. The sources opened for this page include work on peptide activity in the spleen during aging. Study details are limited.

Epitalon (epithalon) is a synthetic tetrapeptide associated with pineal peptide research, largely from one group of laboratories. Published papers include cell-culture work on circadian-gene expression, a transgenic mouse mammary-tumor model, and a small retinitis pigmentosa report. Independent clinical trials are limited.

FOXO4-DRI is a designed peptide used in senescence research. A 2017 Cell paper reported that targeting senescent cells with this peptide restored tissue homeostasis in chemotoxicity and aging models in mice. Later work has also examined possible adverse effects in other disease models.

In stock at Savannah

NAD+ is a cellular coenzyme, not a ribosomal peptide. Interest in NAD+ and its precursors (such as nicotinamide riboside and nicotinamide mononucleotide) comes from aging and metabolic research. Clinical evidence for direct NAD+ administration is more limited than the biochemical literature, and systematic reviews have been cautious.

View NAD+ in the catalog

In stock at Savannah

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that has been studied in primary mitochondrial myopathy and in Barth syndrome. Phase 2/3 and extension papers have been published. A research vial is not the investigational or licensed clinical product.

View SS-31 in the catalog

Thymalin is a thymus-derived polypeptide preparation studied mainly in older Russian clinical and gerontology papers, including infection and surgical settings. The preparation is not a single fully defined sequence, and much of the literature is dated. It should not be confused with thymosin alpha-1.

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid thymic peptide that has been studied as an immunomodulatory agent, including in chronic hepatitis and in sepsis. Licensed or registered products exist in some countries. A research vial is not those pharmaceutical products.

Vesugen is a short peptide from the same bioregulatory research line as several other vascular and brain peptides. Published papers are limited, often observational, and sometimes pool several peptides, so findings should be read cautiously.

Growth hormone axis

12

CJC-1295 without DAC is a short-acting analog of growth hormone-releasing hormone fragment 1–29. It is chemically distinct from CJC-1295 with DAC, which carries an albumin-binding moiety that markedly prolongs circulation. Much of the formal human literature describes GHRH(1–29) itself rather than this exact analog.

BlendIn stock at Savannah

This research blend combines a short-acting GHRH analog (CJC-1295 without DAC) with ipamorelin, a growth-hormone secretagogue. Each component has been studied on its own. Indexed primary papers of this specific two-peptide research blend were not among the sources opened for this page.

View CJC-1295 (no DAC) + Ipamorelin Blend in the catalog

CJC-1295 with DAC is a GHRH analog covalently modified so that it binds serum albumin, extending its time in circulation. Healthy-adult trials in the mid-2000s examined growth-hormone and IGF-I responses after subcutaneous doses.

Savannah lists this item as a synthetic peptide fragment designated Frag 17-23. Published growth-hormone research more often describes other fragments, especially the C-terminal 176–191 region (including the analog AOD-9604). In the sources opened for this page, no primary study was verified that clearly investigates a growth-hormone 17–23 fragment under that name, so no study-dosing details are listed here.

GHRP-2 (pralmorelin) is a hexapeptide growth-hormone secretagogue that acts at the ghrelin receptor. It has been studied in children with short stature, in critically ill adults, and in experimental endocrine protocols.

GHRP-6 is an early growth-hormone-releasing peptide used in endocrine research. Human studies have examined GH, ACTH, cortisol, and sleep after administration, and a pharmacokinetic study measured plasma levels in healthy men.

IGF-1 DES (des(1–3)IGF-I) is a truncated form of insulin-like growth factor I that binds poorly to some IGF-binding proteins and has been studied mainly in animals and in biochemical work, not as an approved human drug.

IGF-1 LR3 is an analog of insulin-like growth factor I with an N-terminal extension and an arginine substitution at position 3, designed to reduce binding-protein interaction. Published work is largely in animals and in biochemical anabolic models.

Ipamorelin is a pentapeptide growth-hormone secretagogue developed as a more selective GH-releasing peptide. Human volunteer studies have described its pharmacokinetics, and a later proof-of-concept trial examined it for postoperative ileus.

Sermorelin is synthetic growth hormone-releasing hormone fragment 1–29, formerly used as a diagnostic and therapeutic product in children with growth-hormone deficiency. Clinical papers from the 1990s examined GH stimulation and longer-term endocrine effects. A research vial is not a currently marketed branded drug product.

Tesamorelin is a stabilized analog of growth hormone-releasing hormone. A licensed product has been studied in people with HIV-associated lipodystrophy and, later, in HIV-associated fatty liver disease. A research vial is not the licensed pharmaceutical product.

Hexarelin is a synthetic growth-hormone secretagogue related to the GHRP family. Human studies in the 1990s and early 2000s examined GH responses, longer-term GH status, and cardiac performance. Savannah does not currently list a hexarelin product; it is included because the clinical-research record is relatively clear.

Neuropeptide

7

Gonadorelin is synthetic gonadotropin-releasing hormone, the hypothalamic decapeptide that drives luteinizing hormone and follicle-stimulating hormone release. Pulsatile GnRH pumps and related protocols have been studied in hypogonadotropic hypogonadism and for ovulation induction. It is a licensed medicine in some countries in specific indications.

Kisspeptin-10 is a short peptide from the KISS1 gene product that stimulates GnRH neurons via the KISS1 receptor. Clinical-research papers have used it to probe gonadotropin secretion in healthy volunteers and in metabolic conditions.

Orexin A (hypocretin-1) is a hypothalamic neuropeptide involved in wakefulness and autonomic control. Small clinical-research studies have used intranasal orexin A in narcolepsy and in healthy volunteers. It is distinct from orexin-receptor agonist drugs in development.

Orexin B (hypocretin-2) is the second peptide from the same precursor as orexin A. Published work is mainly in animals and in neuronal physiology, including dopaminergic midbrain neurons. Human trial literature is thinner than for orexin A.

Oxytocin is a hypothalamic nonapeptide hormone with licensed obstetric and lactation uses as a medicine. A large research literature has also examined intranasal oxytocin in social cognition, autism, and schizophrenia. Those research protocols are not instructions for a laboratory vial, which is not a licensed medicine.

PT-141 (bremelanotide) is a cyclic peptide developed from the melanotan series. An injectable bremelanotide product was studied in two randomized phase 3 trials for hypoactive sexual desire disorder in premenopausal women and later approved in that medical setting. A research vial is not the licensed product.

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide. An intravenous or inhaled form (aviptadil) has been studied in pulmonary hypertension and, more recently, in COVID-19 respiratory failure, with mixed results in larger trials. A research vial is not a licensed aviptadil product.

Other research compounds

3

Erythropoietin (EPO) is the glycoprotein hormone that stimulates red-blood-cell production. It is a licensed medicine in specific medical settings and is also a prohibited substance in sport. The literature is extensive. A research vial is not a licensed pharmaceutical product and is not for human use.

Glutathione is a naturally occurring tripeptide used as a cellular antioxidant in biochemistry. Clinical research has examined oral, intravenous, and intranasal forms in several settings, including Parkinson’s disease and dermatology. A research-grade vial is not a licensed drug product.

PNC-27 is a synthetic peptide related to the p53–HDM2 interaction that has been studied for membrane pore formation in cancer-cell models. Published work is preclinical or early translational; it is not an approved cancer medicine.

For research use only. Not for human consumption.

⚠ For research use only. Not for human consumption. All products are sold strictly for laboratory and educational research by qualified professionals. Not a drug, food, or cosmetic. Not intended to diagnose, treat, cure, or prevent any disease.